Concepedia

Angelika Hanschmann

AH

Statistics

Publications

15

Citations

733

H-Index

14

Active since

2007

Affiliations

MerLion Pharma (Germany)(Current)

Baylor College of Medicine

Shirley Ryan AbilityLab

Centre for Movement Disorders

University Hospital Olomouc

Angelika Hanschmann is an author at MerLion Pharma (Germany) specializing in medicine, botulinum toxin treatment, and neurology.

Publications per year

2007–2022

15

Publications

15

Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia

Cynthia Comella, Joseph Jankovic, Daniel Truong et al. · Journal of the Neurological Sciences · 2011 · 143 citations

Medicine, Neurology, Neuroscience +14

Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—A randomized trial

Joseph Jankovic, Cynthia Comella, Angelika Hanschmann et al. · Movement Disorders · 2011 · 94 citations

Medicine, Neurology, Pharmacology +11

Randomized, placebo‐controlled trial of incobotulinumtoxina for upper‐limb post‐stroke spasticity

Elie P. Elovic, Michael C. Munin, Petr Kaňovský et al. · Muscle & Nerve · 2015 · 74 citations · Full text

Medicine, Neurology, Functional Movement Assessment +14

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia

Virgilio Gerald H. Evidente, Hubert H. Fernandez, Mark S. LeDoux et al. · Journal of Neural Transmission · 2013 · 71 citations · Full text

Medicine, Neurology, Pharmacotherapy +14

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm

Daniel Truong, Stephen Gollomp, Joseph Jankovic et al. · Journal of Neural Transmission · 2013 · 66 citations · Full text

Medicine, Neurology, Pharmacology +14

1–5 of 15